AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02673658 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: body weight support training
Description: Mobility tasks to change positions or move the body with assistance to initiate movement
Study NCT03738865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Study NCT03738865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-Pen
Description: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector
Study NCT03738865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novo Glucagon
Description: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
Study NCT03738865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novo Glucagon
Description: 1 mg subcutaneous injection of Novo Glucagon (glucagon injection)
Study NCT00535301 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sutured anterior vaginal prolapse repair
Description: anterior vaginal prolapse repair with suture
Study NCT01955031 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemonitoring
Description: A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
Study NCT01955031 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
Study NCT03121989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Pyruvate (13C) Injection
Description: The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
Study NCT03121989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Coil Testing
Description: Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
Study NCT03121989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NAC
Description: Participants will be receiving NAC as part of their clinical treatment.
Study NCT03121989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NAC
Description: Participants will be receiving NAC as part of their clinical treatment.
Study NCT02305329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study NCT02623062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Compound Sodium Alginate Oral Suspension sachet
Description: Contents of 2 sachets taken four times daily for 7 days
Study NCT00358670 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: infliximab
Description: Infliximab maintenance therapy~intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2).
Study NCT00358670 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: infliximab
Description: Infliximab intermittent therapy:~Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 \[NCT00251641\] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse.
Study NCT01834365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Structured education
Description: Formatted education about hypertension
Study NCT02623062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Contents of 2 sachets taken four times daily for 7 days
Study NCT04067856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Intravitreal injection
Study NCT01834365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured education
Description: Formatted education about hypertension
Study NCT01834365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist
Study NCT01834365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without structure education with checklist
Study NCT03582306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High chlorophyll diet - intervention 1st
Description: Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the first 4 week period of the study.
Study NCT03582306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High chlorophyll diet - control 1st
Description: Participants will be provided frozen dark leafy green vegetables, and counseled to consume 1 cup cooked dark green leafy vegetables (2 servings) daily over the 4 week period while maintaining their normal red meat intake. This will occur during the last 4 week period of the study.
Study NCT02660359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
Study NCT02660359 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT02660359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT02660359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT00875394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: sitagliptin 100 mg Once a day (QD) for 24 weeks
Study NCT00875394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: metformin
Description: metformin 850 mg Twice a day (BID) for 24 weeks
Study NCT00875394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin
Description: metformin 850 mg Twice a day (BID) for 24 weeks
Study NCT00875394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin
Description: metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
Study NCT00875394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Antidiabetic Standard of Care
Description: Patient can take any oral antidiabetic drug (other than metformin)
Study NCT04440111 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One year training
Description: At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015.~After that, they will make a practical workshop on BLS. Finally they will repeat the initial test. The second year, this group will only make the test, they won't receive any theory or practice.
Study NCT04440111 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Two years training
Description: At first, children will make a test to evaluate their pre- intervention basic support life knowledge.~Secondly, they will receive a theoretical class about BLS, based on European Resuscitation Council Guide 2015. After that they will make a practical workshop on BLS.~Finally they will repeat the initial test. The second year, this group will repeat the same process.
Study NCT00119444 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periacetabular osteotomy
Description: osteotomy of the pelvis to increase acetabular coverage
Study NCT04100226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1.25 (OH)2 cholecalciferol)
Description: Vitamin D 3 in a dose of 200.000 IU intramuscular injection every 2 weeks for 3 months for Vitamin D deficient interstitial lung disease patients and every month for 3 months for vitamin D insufficient interstitial lung disease patients.~calcium supplementation in form of ca carbonate 600 mg oral capsule once daily for 3 months for all patients.
Study NCT04596163 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Transversus thoracis muscle plane block
Description: After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
Study NCT04596163 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus thoracis muscle plane block
Description: After general anaesthesia, transversus thoracis plane (TTP) block, a kind of regional block will be performed near both sides of the sternum under ultrasound guidance using either levobupivacaine or normal saline to both groups of patients. The end point for injection is the fluid spread along the plane just superficial to the transversus thoracis muscle, together with the downward displacement of the pleura.
Study NCT02677545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Study NCT02677545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study NCT02677545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Study NCT02677545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT04537091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rESWT
Description: rESWT was administered once per week for 3 weeks with 4 bar pneumatic pressure, 10 Hz frequency, with 2000 pulses. Radial shock waves were transmitted to the greater trochanteric region with the maximum pain/tenderness that was identified with patients' reaction with small circular movements with an adequate amount of contact gel
Study NCT04537091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRP injection
Description: PRP injection is performed with a high resolution 7-12-megahertz linear probe ultrasonography device. 15 ml of blood will be drawn from the patients and the blood will be centrifuged for 5 minutes. 4-5 ml PRP will be injected into the affected gluteal tendons accompanied by ultrasonography.
Study NCT01100177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5mg/m2/d
Study NCT01100177 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation therapy (60Gy) 2 Gy per day during 30 days
Study NCT02528201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200 milligrams
Description: Celecoxib 200 milligrams once a day
Study NCT02528201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400 milligrams
Description: Celecoxib 400 milligrams once a day
Study NCT02528201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac 50 milligrams
Description: diclofenac 50 milligrams three times a day
Study NCT01585064 — intervention group
Intervention type: OTHER
Intervention: DAS28-IOMS
Description: Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of \< 2.4.
Study NCT01585064 — intervention group
Intervention type: OTHER
Intervention: 0SJ-IOMS
Description: Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
Study NCT01585064 — intervention group
Intervention type: OTHER
Intervention: Routine Care (RC)
Description: Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
Study NCT04426019 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CLS Intervention
Description: Community health workers (or promotoras) will deliver the CLS program either in face-to-face and/or group sessions to all women within 2 months of the baseline interview. Each session will last approximately 1 to 2 hours, and will include CLS materials adapted for this study.At the conclusion of the CLS program, promotoras will provide information about local and affordable providers delivering low-cost or free breast and cervical cancer screening services. Should a woman require follow-up for abnormal results, referrals will be given to programs,which provides assistance accessing cancer diagnostic and treatment services. Two weeks after delivering the education component of the CLS program, promotoras will call women to provide any further assistance needed. During these follow-up calls promotoras will provide on-going navigation support to women in need of mammography and Pap test screening
Study NCT04426019 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No CLS intervention
Description: This control arm will receive only usual practice care (print education) and will not receive the CLS intervention. They may receive the intervention after the study has been completed
Study NCT01076595 — intervention group
Intervention type: DRUG
Intervention: Interferon beta-1b (Betaseron, BAY86-5046)
Description: Betaferon 250 microgram
Study NCT00803894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK0752
Description: Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
Study NCT00803894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: MK0752.
Description: Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
Study NCT00803894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Single dose placebo capsules: there will be a 7-day washout period between treatments.
Study NCT04057118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-O-703
Description: Oral administration, twice per day
Study NCT01252251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (Everolimus) and Pasireotide (SOM230) LAR
Description: Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
Study NCT06250621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement
Description: Implants were placed by means of a template for a guided surgery approach (GD Group) or with a standard free-hand surgical approach without any additional device (FH Group). A non expert doctor (less that 20 implants placed in the professional activity) was selected for the procedures related to the GD Group; a skilled operator (more than 1000 implants placed in the professional activity) was selected for the procedures related to the FH Group, respectively.~A two-stage surgical technique was chosen. Implants were placed (Anyridge, Megagen Implants, Seoul, Korea) 1 mm below the crestal level, as recommended by the manufacturer. After flap elevation the height of the supra-crestal soft tissue (STH) was measured by means of a calibrated probe.~An inter-implant distance of 3 mm at least, and/or an interproximal space from 1.5 to 3 mm between an implant and the adjacent tooth were observed.~Flaps were sutured over the implants to allow a submerged healing.
Study NCT04057118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, twice per day
Study NCT00833976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovaza
Description: 4 grams per day
Study NCT01853449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Study NCT01853449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Study NCT03725722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application
Study NCT01853449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CWS
Description: Chest wall strapping to reduce vital capacity by 20% of its baseline value
Study NCT01853449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CWS
Description: Chest wall strapping to reduce vital capacity by 20% of its baseline value
Study NCT01853449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT01834820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine and Dexamethasone
Study NCT01834820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Study NCT01834820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Study NCT04199247 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sub symptom aerobic exercise
Description: Participants will meet with a member of the research team to undergo a bike-based exercise test at the initial test. Heart rate will be obtained at the completion of the test, and intervention participants will be asked to complete exercise at 80% of that level, 5x/week for 20-30 minutes/session over the next two months.
Study NCT03725722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT00288119 — intervention group
Intervention type: DEVICE
Intervention: Balloon Capsule Device
Description: The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize \& protect the site-specific sample collection.
Study NCT03822169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline added as a phospholipid
Description: A shake with 3000 mg choline added as a phospholipid
Study NCT03822169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Choline added as a salt
Description: A shake with 3000 mg choline added as a salt
Study NCT04563858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Validation
Description: Assessment of Polish version of the 4AT
Study NCT02525133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XaraColl
Description: Surgical implantation of 3 bupivacaine collagen implants
Study NCT02525133 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plain collagen implant (vehicle)
Study NCT00111657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: 8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5